OrbiMed Advisors acquires $10 million of BlossomHill Therapeutics common shares
Reuters2026/08/12 20:44- OrbiMed Advisors reported a higher stake in Blossomhill Therapeutics, ending with 2,714,279 shares of common stock held indirectly.
- Position increase reflected 625,000 shares bought in the IPO at $16.
- Holdings also rose through conversion of Series A and Series B preferred stock into 2,089,279 common shares.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Faraday Future adds government procurement veteran Steven Newton as senior strategic advisor
JPMorgan: Tesla (TSLA.US) Robotaxi revenue may reach $320 billions by 2035, with nearly 98% coming from its own fleet
JPMorgan analyst Rajat Gupta released a research report last week, estimating that by 2035, Tesla's Robotaxi revenue will reach approximately $320 billion, with nearly $314 billion coming from Tesla's own and operated fleet, rather than from the owner-operated "Tesla Network."
FDA approves Telix brain cancer imaging drug Pixclara for glioma PET scans
Charles Hoskinson Says AI Has Destroyed The Old Crypto Growth Metric
Crypto prices
More
